Literature DB >> 31423207

Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma.

Li Li1,2, Yinghua Li3, Zhuomin Yin1, Jing Zhu1, Dingding Yan1, Hanmei Lou1,2.   

Abstract

The aim of the present study was to investigate the frequency of cluster of differentiation (CD)4+CD25+CD127- regulatory T cells (Tregs) in the peripheral blood mononuclear cells (PBMCs) of patients with endometrioid adenocarcinoma (EA). A total of 82 female patients with EA were recruited. The PBMCs were flow cytometrically analyzed to determine the percentage of CD4+CD25+CD127- Tregs within the CD4+ T cell population. The associations between the prevalence of Tregs in PBMCs and defined clinical prognostic parameters were evaluated. To study the immunoregulatory capacity of Tregs, the level of specific cytokines were detected by ELISA, and the proliferation of cells was analyzed by incorporation of 3H-thymidine. It was revealed that Treg/CD4+ ratio in the peripheral blood of patients with EA was 4.89±1.42%, significantly higher than Treg/CD4+ ratio in healthy women. No correlation was observed between Treg frequency and stage, grade of differentiation, menopausal status or age. CD4+CD25+CD127- Tregs secreted large amounts of IL-10 but not IFN-γ. The level of IL-10 secreted by Tregs from patients with EA and healthy controls was not significantly different. In addition, there was no significant difference in the suppressive activity of Tregs in patients with EA compared with that of the healthy controls. These findings demonstrate that the increased frequency of immunosuppressive Tregs in patients with EA may be responsible for immune tolerance in endometrial cancer.

Entities:  

Keywords:  Treg cells; endometrial cancer; endometrioid adenocarcinoma; interleukin-10; peripheral blood

Year:  2019        PMID: 31423207      PMCID: PMC6607055          DOI: 10.3892/ol.2019.10452

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

Review 1.  T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases.

Authors:  K M Murphy; W Ouyang; S J Szabo; N G Jacobson; M L Guler; J D Gorham; U Gubler; T L Murphy
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

2.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

Authors:  Yasmine Belkaid; Ciriaco A Piccirillo; Susana Mendez; Ethan M Shevach; David L Sacks
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

3.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

4.  Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.

Authors:  Nicolas Larmonier; Marilyn Marron; Yi Zeng; Jessica Cantrell; Angela Romanoski; Marjan Sepassi; Sylvia Thompson; Xinchun Chen; Samita Andreansky; Emmanuel Katsanis
Journal:  Cancer Immunol Immunother       Date:  2006-04-13       Impact factor: 6.968

5.  Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.

Authors:  Laura Tsaknaridis; Leslie Spencer; Nicole Culbertson; Kevin Hicks; Dorian LaTocha; Yuan K Chou; Ruth H Whitham; Antony Bakke; Richard E Jones; Halina Offner; Dennis N Bourdette; Arthur A Vandenbark
Journal:  J Neurosci Res       Date:  2003-10-15       Impact factor: 4.164

6.  Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Gabriella Ferrandina; Alessia Buzzonetti; Francesco Legge; Vanda Salutari; Giovanni Scambia
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

Review 7.  Are regulatory T-cells linked with aging?

Authors:  Christian Dejaco; Christina Duftner; Michael Schirmer
Journal:  Exp Gerontol       Date:  2006-03-03       Impact factor: 4.032

Review 8.  Follow-up after primary therapy for endometrial cancer: a systematic review.

Authors:  Michael Fung-Kee-Fung; Jason Dodge; Laurie Elit; Himu Lukka; Alex Chambers; Tom Oliver
Journal:  Gynecol Oncol       Date:  2006-03-23       Impact factor: 5.482

9.  An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.

Authors:  C Asseman; S Mauze; M W Leach; R L Coffman; F Powrie
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

10.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  2 in total

Review 1.  Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?

Authors:  Christine De Bruyn; Thaïs Baert; Thierry Van den Bosch; An Coosemans
Journal:  Curr Oncol Rep       Date:  2020-01-29       Impact factor: 5.075

2.  Development of Biomarker Signatures Associated with Anoikis to Predict Prognosis in Endometrial Carcinoma Patients.

Authors:  Shan Chen; Jiamin Gu; Qinfen Zhang; Yan Hu; Yu Ge
Journal:  J Oncol       Date:  2021-12-28       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.